Bayer reported an important drop in benefit. The cause of this was once deficient industry within the agricultural house. In keeping with the pharmaceutical and agricultural staff, custom designed working benefit (EBITDA) fell 22 p.c to two.35 billion euros within the fourth quarter of 2024. years. Analysts anticipated a mean of two.26 billion averages.
The sale fell a just right proportion to 11.73 billion euros, and that was once roughly on the remaining yr. For all the yr, Leverkuzen reported site visitors from 46.6 (2023: 47.64) billions of euros and a custom designed results of 10.1 (11.7) billion. The decrease line was once a lack of 2.55 billion euros.
Development simplest since 2026
As within the earlier yr, shareholders must obtain dividend 11 cents in step with proportion. Baier compiled a dividend for the following 3 years to scale back the debt a yr in the past.
No brief development is predicted: 2025. years, Bayer expects the consequences of foreign money with gross sales of 45 to 47 billion euros. The adjusted consequence will most definitely fall to 9.3 to 9.8 billion euros. The Board has already lowered the forecast of the effects for 2024. In November because of deficient agricultural operations and invested traders for any other tricky yr. The crowd simplest expects stepped forward efficiency from 2026. Years.
Pharmaceutical trade
Z + (precision content material); Invoice Anderson: The top of which abolishes the heads of Z + (content material matter to registration); Baier AG: Is it on the finish of the arena pharmacy? Global Chemical Convention in Bonn: Tooisome to Europe, just right sufficient for the remainder of the arena
From the takeover of the Monsanto Workforce Agrarchemistry, the Workforce fights with court cases in opposition to the corporate in the US in regards to the weed destroyer Glyphosat. The shareholders known as to split the rural paintings, however Bayer didn’t behavior. The crowd management meets losses with sturdy activity interruptions, particularly in control.
